•  
  •  
 

Abstract

Lemongrass is a common ingredient in Indonesian traditional herbal medicine that potently inhibits carbohydrate hydrolysis. In this study, the in vitro α-glucosidase inhibitory (AGI) activity of lemongrass was compared with its in vivo activity to retard postprandial blood glucose elevation, and the bioactive compounds responsible for these activities were observed. Both water and ethanolic extracts of lemongrass (WLG and ELG, respectively) were tested in vitro for its inhibition of the sucrose and maltose hydrolyzing activities of rat intestinal glucosidase. ELG was observed to exert higher inhibitory activities (Sucrase IC50 = 8.74 mg/mL; Maltase IC50 = 18.93 mg/mL) than WLG. ELG was evaluated for its in vivo activity to retard blood glucose elevation in mice after sucrose, maltose, and glucose consumption. ELG was also fractionated using activity-guided chromatography, followed by liquid chromatography–mass spectrometry and high-performance liquid chromatography (HPLC). In vivo sugar tolerance test confirmed the AGI activity in a non-dose-dependent manner and showed potential additional mechanisms that may prevent postprandial hyperglycemia. The active principles were acquired in methanol-soluble fraction and purified using preparative thin-layer chromatography. HPLC analysis with commercial standards identified caffeic acid and kaempferol as the compounds responsible for the bioactivity of ELG. Results showed that lemongrass has the potential as herbal medicine ingredient in the management of diabetes.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.